ABSTRACT
Fever in the neutropenic cancer patient is among the most serious complications related to chemotherapy, and is also among the most common. Management of this complication can vary widely, relating to differing geographic patterns of commonly infecting organisms and of antimicrobial resistance, as well as issues of treatment availability and cost containment. To help promote evidence-based quality improvements in the care of cancer patients with neutropenic fever, a number of societies have developed clinical practice guidelines.
